argenx to present at JP Morgan HC, Jan 10 2019 - 10 AM PT, San Francisco: Presentation and Q&A

NHance®

NHance® is argenx’ proprietary approach to prolong antibody circulation time and enhance antibody tissue distribution.

Based on two specific mutations in the antibody Fc region, NHance® enables half-life extension without increasing immunogenicity or compromising manufacturability. NHance® has no adverse effects on Fc-mediated cell destruction and is applicable to both antibody and Fc fusion protein products.

NHance® provides a new treatment paradigm through:

  • Increased product efficacy, improved biodistribution, enhanced delivery across mucosal barriers
  • Increased patient convenience: decreased dosage, choice of drug delivery route
  • Improved pharmacoeconomics: reduced dosing requirements, fewer patient visits